Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJardine Math.sr Regulatory News (JAR)

Share Price Information for Jardine Math.sr (JAR)

Share Price is delayed by 15 minutes
Get Live Data
62.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: $18.42b
JAR Live PriceLast checked at - London Stock Exchange

Intraday Jardine Math.sr Share Chart

Interim Management Statement

10 Nov 2022 09:42

RNS Number : 9939F
Mandarin Oriental International Ltd
10 November 2022
 

Announcement

 

The following announcement was issued today to a Regulatory Information Service approved by the Financial Conduct Authority in the United Kingdom.

 

MANDARIN ORIENTAL INTERNATIONAL LIMITED

Interim Management Statement

 

10th November 2022 - Mandarin Oriental International Limited today issues its Interim Management Statement for the third quarter of 2022.

 

The return of normal travel conditions in most of the world in early 2022 saw the Group record net underlying profits (unaudited) in the second quarter, and this progress continued in the third quarter.

 

In the Group's owned hotels, improvements in occupancy and high rates resulted in a stronger performance in the third quarter. This drove increased profitability compared to the second quarter, particularly in Paris and Munich. Two of the Group's key profit-generating hotels, in Hong Kong and Tokyo, however, remained subject to stringent travel restrictions throughout the third quarter, which significantly impacted operating performance. The hotels in Bangkok and Singapore continued their recovery following the removal of travel barriers.

 

The performance of the management business was strong in the third quarter and it recorded a significant improvement in profitability compared to the second quarter. Of particular note were the contributions made by a number of the Group's Mediterranean and Middle Eastern properties.

 

As a result of the improved trading conditions and Mandarin Oriental's expanded portfolio of hotels and residences, the Group recorded its highest quarterly EBITDA since 2019. Both the owned hotels and the management business delivered higher EBITDA than in the second quarter of 2022.

 

In September 2022, the Group opened Mandarin Oriental Palace, Luzern, its second hotel in Switzerland, and its standalone residences project in Barcelona. Recently, the Group announced a new hotel in Tianfu, the new business district of Chengdu, further expanding its presence in China. On 8th September 2022, the Group completed the sale of Mandarin Oriental, Washington D.C., for US$139 million. As a result, the Group has recognised a post-tax, non-trading gain in the third quarter of US$47 million.

 

Following the disposal, net debt at 30th September 2022 reduced to US$385 million (US$519 million at 30th June 2022), and the Group held US$267 million of cash reserves and US$472 million in available, committed debt facilities. Gearing was 8% of adjusted shareholders' funds.

 

Mandarin Oriental International Limited is incorporated in Bermuda and has a primary listing in the standard segment of the London Stock Exchange, with secondary listings in Bermuda and Singapore. Mandarin Oriental is a member of the Jardine Matheson Group.

 

- end -

 

For further information, please contact:

Mandarin Oriental Hotel Group International Limited

James Riley

(852) 2895 9288

Matthew Bishop

(852) 2895 9288

Brunswick Group Limited

William Brocklehurst

(852) 5685 9881

 

This and other Group announcements can be accessed through the Internet at 'www.mandarinoriental.com'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCKBLBFLFLXFBK
Date   Source Headline
29th May 202610:53 amRNSTotal Voting Rights
29th May 202610:47 amRNSDirector/PDMR Shareholding
28th May 202611:31 amRNSTransaction in Own Shares
27th May 202610:27 amRNSDirector/PDMR Shareholding
26th May 20267:00 amRNSAcquisition of I-MED Radiology Network
22nd May 202610:23 amRNSInterim Management Statement
19th May 202612:22 pmRNSINTERIM MANAGEMENT STATEMENT
18th May 202612:57 pmRNSNotification of Issuance of Equity Securities
18th May 202612:30 pmRNSDirector/PDMR Shareholding
7th May 20261:01 pmRNSAdditional Listing
7th May 202612:49 pmRNSDirector/PDMR Shareholding
7th May 202612:44 pmRNSResult of AGM
5th May 202610:54 amRNSTransaction in Own Shares
5th May 202610:19 amRNSTransaction in Own Shares
30th Apr 202611:51 amRNSTotal Voting Rights
30th Apr 202611:50 amRNSTransaction in Own Shares
30th Apr 202610:47 amRNSJC&C Interim Management Statement
29th Apr 202612:28 pmRNSPT Astra 2026 First Quarter Financial Statements
29th Apr 202611:59 amRNSTransaction in Own Shares
29th Apr 202610:48 amRNSDividend
28th Apr 202611:35 amRNSTransaction in Own Shares
28th Apr 20267:00 amRNSTransaction in Own Shares
24th Apr 202611:26 amRNSDividend
22nd Apr 202611:12 amRNSTransaction in Own Shares
21st Apr 202610:57 amRNSTransaction in Own Shares
20th Apr 202611:01 amRNSTransaction in Own Shares
14th Apr 202611:31 amRNSTransaction in Own Shares
13th Apr 202611:27 amRNSTransaction in Own Shares
10th Apr 202611:23 amRNSTransaction in Own Shares
8th Apr 202611:53 amRNSTransaction in Own Shares
8th Apr 202610:25 amRNSAnnual Financial Report
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20268:02 amRNSTransaction in Own Shares
1st Apr 202611:17 amRNSTransaction in Own Shares
1st Apr 202610:34 amRNSCirc re. Scrip Dividend Scheme
1st Apr 202610:21 amRNSDirector/PDMR Shareholding
31st Mar 202611:59 amRNSDirector/PDMR Shareholding
31st Mar 202611:53 amRNSTotal Voting Rights
31st Mar 202611:46 amRNSTransaction in Own Shares
30th Mar 202611:08 amRNSTransaction in Own Shares
27th Mar 20269:43 amRNSDirector/PDMR Shareholding
25th Mar 202611:05 amRNSDirector/PDMR Shareholding
25th Mar 202610:31 amRNSTransaction in Own Shares
25th Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 202611:07 amRNSTransaction in Own Shares
20th Mar 20269:26 amRNSDirector/PDMR Shareholding
17th Mar 20269:55 amRNSDirector/PDMR Shareholding
16th Mar 20269:57 amRNSDirector/PDMR Shareholding
16th Mar 20269:57 amRNSDirector/PDMR Shareholding
13th Mar 20269:42 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.